George Badescu
Chief Business Officer Heidelberg Pharma
Seminars
Wednesday 10th June 2026
Why Payload Matters: Amanitin From Molecular Mechanism to Clinical Application
11:30 am
- Explore how Amanitin‑based ADCs address limitations of traditional cytotoxic payloads through a novel MoA (RNA Pol II inhibition) that can overcome resistance
- Discover how HDP‑101 illustrates the translational path for a first‑in‑class Amanitin payload
- Discuss how an Phase I/IIa, HDP‑101 showed objective responses, including complete remissions below the MTD in heavily pretreated RRMM patients
